Introduction
Anti-cancer drugs have been shown to target diverse cellular functions in mediating cell death in chemosensitive tumors. Cytotoxic drugs which are currently used for the treatment of malignant diseases such as cytarabine, doxorubicin, methotrexate, etoposide and cisplatin are thought to exert their effects through inhibition of DNA-polymerase (cytarabine), DNA-intercalation (doxorubicin), antagonization of folic acid (methotrexate), inhibition of topoisomerase II (etoposide) and DNA-crosslinking (cisplatin). 1 In addition, it has been recently shown that most antineoplastic drugs used in chemotherapy of leukemias and solid tumors induce apoptosis in drug-sensitive target cells. However, the precise molecular requirements that are central for drug-induced cell death are largely unknown.
Apoptosis is a highly conserved physiological process important in normal development and tissue homestasis of multicellular organisms with characteristic morphological features such as membrane blebbing, nuclear condensation and fragmentation. 2 Physiological apoptosis can be induced by a multitude of stimuli, including withdrawal of growth factors and hormones, inappropriate expression of oncogenes, and activation of death receptors such as CD95 (APO-1/Fas) and tumor necrosis factor-receptor type I (TNF-RI).
The CD95 pathway
The CD95 receptor/CD95 ligand (CD95/CD95-L) system has been described as a key signal pathway involved in regulation of apoptosis in several cell types. [3] [4] [5] [6] The CD95, a 48 kDa type I transmembrane receptor (CD95) is a member of the tumor necrosis factor/nerve growth factor (TNF/NGF) receptor superfamily of cell surface molecules which includes various molecules involved in immune regulation, such as TNF receptors I and II, CD27, CD30 and CD40. [7] [8] [9] [10] [11] [12] CD95 crosslinking by agonistic antibodies or the natural ligand activates a signal cascade via FADD/MORT-1 and FLICE/MACH (caspase-8) that directly leads to activation of ICE/Ced-3 proteases (caspases) which function as downstream effectors of cell death. [13] [14] [15] After receptor multimerization caspase-8 (FLICE) is recruited via FADD into the DISC (death-inducing signaling complex). FLICE is a chimeric molecule that contains an adaptor domain able to bind to FADD as well as a proteolytic domain similar to caspase providing the link between the DISC and the proteolytic cascade that exerts the death signal ( Figure 1) . 14, 15 The CD95 ligand (CD95-L), a type II transmembrane molecule of 40 kDa, is a member of the corresponding family of TNF-related cytokines, which is found in a soluble or membrane-bound form. The CD95-L is produced by activated T cells and is constitutively expressed in a variety of tissues. Constitutive CD95-L expression may constitute a mechanism of immune privilege in several anatomical sites and tumors. 16, 17 In growth control of T cells CD95-L may cause autocrine suicide in sensitive CD95
+ T cells and fratricide or paracrine death in neighbouring T cells or other target cells. [18] [19] [20] Although the key role of the CD95 system in negative growth regulation has been studied mostly within the immune system, recent evidence suggests that activation of this system such as induction of CD95-L, upregulation of CD95 and activation of caspases contributes to chemosensitivity of tumor cells.
Evidence for an involvement of apoptosis pathways in druginduced apoptosis also comes from studies on the proteins of the Bcl-2 family which play a critical role in regulation of apoptosis pathways through homo-and heterodimerization. [21] [22] [23] [24] The ratio of pro-apoptotic Bcl-2-related proteins such as Bax and Bcl-x S to anti-apoptotic family members including Bcl-2 and Bcl-x L dictates the susceptibility of cells to various apoptotic stimuli. Modification of apoptosis signals and decision on life or death of cells seem to depend on the balance of pro-apoptotic and anti-apoptotic homo-or heterodimers of this molecule family. Overexpression of Bcl-2 and Bcl-x L in tumor cells has been found to inhibit apoptosis following drug treatment and overexpression of Bax or Bcl-x S was found to be important for apoptosis sensitivity in response to chemotherapeutic agents. [23] [24] [25] [26] However, inhibition of CD95-induced apoptosis by Bcl-2 is variable and may depend on cell type-specific function of the death inducing signaling complex which leads to direct activation of caspases (type I Figure 1 CD95 pathway. EXT, extracellular side; CYT, cytoplasmic side. cells) or alternatively may require additional amplification by Bcl-2 inhibitable mitochondrial activation (type II cells). [27] [28] [29] [30] In type II cells a low level activation of caspases (FLICE) leads to activation of mitochondrial permeability transition mediated by Bid. 28, 29 Signaling through the CD95 receptor may also be modulated by FLIP proteins (for FLICE-inhibitory protein). FLIP interacts with the adaptor protein FADD and the protease FLICE and inhibits apoptosis induced by human death receptors. 31, 32 FLIP is predominantly expressed in muscle and lymphoid cells and may be involved in tissue homeostasis as a regulator of apoptosis.
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CD95 and drugs
We have recently identified that activation of the CD95 system by cytotoxic drugs is involved in drug-induced apoptosis in some cell types. [33] [34] [35] [36] [37] Induction of CD95-L and upregulation of CD95 was observed after treatment of different tumors with cytotoxic drugs such as doxorubicin, cisplatin, methotrexate, cytarabine and etoposide at therapeutic concentrations. [33] [34] [35] [36] [37] Treatment of leukemias or solid tumors, including neuroblastoma, hepatoblastoma, medulloblastoma, colon carcinoma and breast cancer cells with cytotoxic drugs induces CD95-L expression and mediates autocrine suicide or paracrine cell death following binding to its receptor (Figure 2) . [33] [34] [35] [36] [37] Activation of the CD95 system by cytotoxic drugs has also been observed in ex vivo-derived cells from patients with malignant diseases. 37 Blockade of CD95-L/receptor interaction using antagonistic antibodies to the receptor markedly reduced drug-triggered apoptosis. [33] [34] [35] [36] 38 Thus, production of CD95-L and crosslinking of its cognate receptor are probably involved in drug-mediated cell death. Moreover, CD95 expression was unregulated upon treatment with cytotoxic drugs, which increases sensitivity of physiological apoptotic signals. 35, 36 Caspases are centrally involved as death effector molecules during drug-induced apoptosis as the broad-spectrum tripeptide inhibitor of caspases zVAD-fmk almost completely inhibited drug-induced apoptosis. 39 Activation of caspases after drug treatment resulted in cleavage of substrates such as poly(ADP-ribose)polymerase (PARP), an enzyme involved in DNA repair, and one of the known substrates for caspases, and in cell death. 40 Chemosensitivity for drug-induced apoptosis has been reported to depend on activation of caspases. 39 This demonstrates that an intact CD95/CD95-L system and CD95 pathway involving activation of caspases are involved in drug-induced apoptosis in chemosensitive tumor cells.
In addition, recent study shows that patients with CD95-positive AML undergoing chemotherapy as compared to
Figure 2
Activation of the CD95 pathway by anticancer drugs. [42] [43] [44] This clearly shows that upregulation of CD95 in tumor cells by cytokines or cytotoxic drugs may be involved in tumor regression by immune cells.
CD95 and drug-resistance
Primary and secondary resistance to chemotherapy is a central problem in cancer treatment. 45 Resistance towards chemotherapy may result from failure to activate apoptosis pathways in response to drug treatment. 37, 46 The CD95 pathway plays a role in determining sensitivity or resistance towards chemotherapy. 37 Resistance to physiological death signaling such as CD95-induced apoptosis is associated with cross-resistance to therapeutic concentrations of chemotherapeutic agents. 33, 37 In addition, drug resistance is also associated with cross-resistance to anti-CD95 antibody in comparison to parental cells. 37 Resistant cells did not only exhibit delayed kinetics of apoptosis induction, but also remained capable of proliferative expansion. 37 This demonstrated that triggering of cell death either by anti-CD95 or by cytotoxic drugs requires, at least in part, identical pathways. 37 Cell lines resistant to anti-CD95 or cytotoxic drugs showed marked downregulation of CD95 expression, suggesting that critical levels of CD95 expression are required for apoptotic signaling and chemosensitivity. 37 Furthermore, cell lines resistant to therapeutic concentrations of cytotoxic drugs or anti-CD95, were deficient in upregulation of CD95-ligand upon drug treatment, that mediated cell death in chemosensitive cells. 37 In addition, cleavage of FLICE, which was cleaved upon drug treatment in chemosensitive cell lines, was completely blocked in drugand CD95-resistant cell lines (Friesen and Debatin unpublished results). Furthermore, PARP was proteolytically cleaved upon drug treatment in chemosensitive cells. However, in drug-and CD95-resistant cell lines cleavage of PARP was completely blocked. 37 Thus downstream effector pathways required for drug-mediated death in chemosensitive cells are not activated in resistant cells.
Several recent reports have suggested that mitochondria may play a major role in the apoptotic process. [47] [48] [49] A crucial, common step in apoptosis is postulated to involve loss of mitochondrial membrane potential through opening of permeability pores, resulting in hyperproduction of reactive oxygen species. 47 Mitochondria were also involved in druginduced apoptosis in chemosensitive cells after drug treatment. However, in drug-and CD95-resistant cells mitochondria were not activated after drug treatment (Friesen and Debatin, unpublished results), suggesting that mitochondria play a crucial role in sensitivity and resistance towards chemotherapy.
Deficient activation of the CD95 pathway and failure to activate the caspase effectors could be due to imbalanced expression of members of the Bcl-2 family of apoptosis modulating proteins. 50 Overexpression of Bcl-2 and Bcl-x L have been shown to inhibit drug-and CD95-induced apoptosis in some system. 23 However, no differences in the expression levels of Bcl-2, Bcl-x L or Bax have been found in drug-and CD95-resistant cells compared to sensitive parental cells. In addition to defects in apoptosis pathways, multi-drug resistant protein (MRP) and the p-glycoprotein (P-gp, MDR-1) 45,51,52 or deficient function of p53 46 are known to confer resistance to tumor cells. Multi-drug resistance is defined by the simultaneous acquisition of cellular resistance to various cytotoxic drugs. Overexpression of p-glycoprotein (P-gp, MDR-1) in cell lines leads to a decrease in intracellular accumulation of drugs concomitant with an increase in drug efflux. 45, 51, 52 However, resistant cells did not exhibit different drug uptake or drug efflux in comparison to sensitive parental cells. 37 Furthermore, no overexpression of p-glycoprotein (P-gp, MDR-1) was found in resistant cells. Thus, the failure to upregulate CD95-L and to undergo apoptosis in response to drug treatment in resistant cells is not due to decreased drug uptake or increased drug efflux suggesting that non-MDR mechanisms are involved in this type of resistance. 37 The p53 protein has been shown to be involved in various forms of apoptosis induced by cytotoxic drugs and ␥-irradiation. 46 By its transcriptional activity, p53 has been shown to express CD95. 53 However, in resistant cells downregulation of CD95 and deficient upregulation of CD95-L are not caused by deficient p53. 37 This shows that activation of the CD95 system by cytoxic drugs plays a role in chemosensitivity and resistance of various tumor types.
CD95 and solid tumors
In addition to leukemia cells, induction of CD95 and CD95-L expression by cytotoxic drugs was also found in a variety of solid tumor cells. Chemosensitivity in vitro was related to increased CD95-L expression and caspase activation. 36, 37 Induction of CD95-L and caspase activity was found in chemosensitive tumor cells including neuroblastoma, medulloblastoma, glioblastoma, Hodgkin's lymphoma, Ewing's sarcoma, colon carcinoma and small cell lung carcinoma cells. Incubation with cytotoxic drugs also resulted in upregulation of CD95 expression, thereby increasing sensitivity towards the CD95 signal. However, there was only a weak induction of CD95-L and processing of caspases in tumor cells which poorly responded to drug treatment such as breast carcinoma and renal cell carcinoma cells. These data suggested that the CD95 system may also contribute to chemosensitivity of solid tumor cells. 36 
Drug-induced CD95-independent pathways
Recent reports have found that drug-induced apoptosis may occur in the absence of CD95/CD95-L interactions. [54] [55] [56] [57] However, induction of CD95-L following drug treatment was also found in these studies. 55, 56 The discrepancy between different results may reflect differences in cell lines used, kinetics, cell culture conditions, drug concentrations and concentrations or effectiveness of blocking antibodies. Drug-induced apoptosis may also involve cell type-specific activation of parallel pathways such as death receptor pathways and mitochondrial pathways. Thus, cell type-specific modulation has been found for the CD95 pathway itself where the death receptor-derived ligand may require amplification by mitochondrial release of apoptogenic factors. Also, the CD95 system may not be a key effector in all instances and may contribute to chemosensitivity of tumor cells only in the early stages of drug treatment. 56 
Conclusions
Sensitivity and resistance of tumor cells for cytotoxic drugs seems to depend on activation of apoptosis pathways which may involve death receptor pathways such as the CD95 system. Treatment with cytotoxic drugs induces CD95 and CD95-L expression that may trigger autocrine or paracrine death and deficiencies in these system may lead to resistance towards chemotherapy. Drug-induced apoptosis also involves alteration of mitochondrial function leading to release of apoptogenic factors. Eventually, activation of downstream caspases determines the cytotoxic effect of anticancer compounds. Activation of the CD95 system upon drug treatment occurs in a variety of tumor cells in vitro and ex vivo. Understanding of molecular requirements for anticancer druginduced apoptosis will have important implications for development of new drugs and may provide a possibility to overcome drug resistance of tumor cells.
